AU2003222449A1 - Medicine for treating cancer - Google Patents

Medicine for treating cancer

Info

Publication number
AU2003222449A1
AU2003222449A1 AU2003222449A AU2003222449A AU2003222449A1 AU 2003222449 A1 AU2003222449 A1 AU 2003222449A1 AU 2003222449 A AU2003222449 A AU 2003222449A AU 2003222449 A AU2003222449 A AU 2003222449A AU 2003222449 A1 AU2003222449 A1 AU 2003222449A1
Authority
AU
Australia
Prior art keywords
medicine
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003222449A
Other languages
English (en)
Inventor
Takeshi Doi
Tatsuhiko Kodama
Chikage Mataki
Masahiro Nishikawa
Toshiaki Oda
Masao Ohkuchi
Shunji Takemura
Masahiro Tamura
Yukiyoshi Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2003222449A1 publication Critical patent/AU2003222449A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ceramic Engineering (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003222449A 2002-04-12 2003-04-11 Medicine for treating cancer Abandoned AU2003222449A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37167502P 2002-04-12 2002-04-12
US60/371,675 2002-04-12
US41257102P 2002-09-23 2002-09-23
US60/412,571 2002-09-23
PCT/JP2003/004602 WO2003086397A1 (en) 2002-04-12 2003-04-11 Medicine for treating cancer

Publications (1)

Publication Number Publication Date
AU2003222449A1 true AU2003222449A1 (en) 2003-10-27

Family

ID=29254452

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003222449A Abandoned AU2003222449A1 (en) 2002-04-12 2003-04-11 Medicine for treating cancer

Country Status (7)

Country Link
US (1) US20050176764A1 (enExample)
EP (1) EP1494670A1 (enExample)
JP (1) JP2005522492A (enExample)
AU (1) AU2003222449A1 (enExample)
MY (1) MY134200A (enExample)
TW (1) TW200407141A (enExample)
WO (1) WO2003086397A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060040986A1 (en) * 2002-12-06 2006-02-23 Kowa Co., Ltd. Erythropoietin production accelerator
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP4634303B2 (ja) * 2003-10-10 2011-02-16 興和株式会社 血管新生抑制薬
EP1735302B1 (en) 2004-02-27 2010-06-16 Eli Lilly And Company 4-amino-piperidine derivatives as monoamine uptake inhibitors
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20090042901A1 (en) * 2005-02-02 2009-02-12 Kowa Co., Ltd. Agent for prevention/therapy of disease caused by keratinocyte growth
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2080759A4 (en) * 2006-10-13 2011-01-12 Kowa Co GAMMA GLOBININDUKTOR
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
JP5683489B2 (ja) 2009-01-12 2015-03-11 アレイ バイオファーマ、インコーポレイテッド ピペリジン含有化合物およびその用途
CA2878082A1 (en) * 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
RU2018145734A (ru) * 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3808921B2 (ja) * 1995-11-20 2006-08-16 興和株式会社 細胞接着阻害剤
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US6605620B1 (en) * 2001-08-30 2003-08-12 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US6867221B2 (en) * 2001-08-30 2005-03-15 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
US20050176764A1 (en) 2005-08-11
TW200407141A (en) 2004-05-16
WO2003086397A1 (en) 2003-10-23
EP1494670A1 (en) 2005-01-12
JP2005522492A (ja) 2005-07-28
MY134200A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
AUPS054702A0 (en) Cancer therapy
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
AU2003224654A1 (en) Photodynamic therapy for pre-melanomas
AU2003232882A1 (en) Prostacyclin derivatives for treating cancer
AU2003275126A1 (en) Hemiasterlin derivatives for treating resistant tumors
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2003212634A1 (en) Compounds useful in the treatment of cancer
EP2561887B8 (en) Cancer therapy sensitizer
EP1594433A3 (en) Cancer therapy sensitizer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2002308642A1 (en) Methods for treating cancer
AU2003280558A1 (en) Method for treatment of cancer
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2002331816A1 (en) A cancer treatment system
AU2003283339A1 (en) Cancer therapy determination
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2002305138A1 (en) Methods and materials for cancer treatment
AU2003242991A1 (en) Apparatus for therapeutic treatments
AU2003298534A1 (en) Method for treating cancer
GB0223325D0 (en) Treating cancer
AU2003272972A1 (en) Method of treatment for cancer
AU2003238722A1 (en) Cancer therapy by modulating cdc42-activity
GB2383538B (en) Cancer treatment
AU2003229429A1 (en) Polyepitopes and mini-genes for cancer treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase